Clinical Trial

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Study acronym: KYLIN-2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-25; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT06574347
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small-Cell Lung Cancer
Enrollment 120 participants
Start Date 2024-08-07
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-21